Larimar Therapeutics, Inc. (LRMR)
Chart Events
Performance Outlook
| Previous Close | 4.94 |
| Open | 4.94 |
| Bid | 4.50 x 1000 |
| Ask | 6.50 x 800 |
| Day's Range | 4.92 - 5.36 |
| 52 Week Range | 1.53 - 10.05 |
| Volume | |
| Avg. Volume | 97,673 |
| Market Cap | 92.094M |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.37 |
| Earnings Date | Mar 23, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.67 |
- GlobeNewswire
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022. The Company’s presentation will take place on Thursday, December 1, 2
- GlobeNewswire
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in Friedreich’s ataxia patients is ongoing and proceeding in line with the Company’s planned timelineLarimar expects to provide an update on the Phase 2 trial in Q2 2023 and anticipates reporting top-line data from both cohorts in 2H 2023Cash of $124.7 million at September 30, 2022 provides projected cash runway into 2H 2024 BALA CYNWYD, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR
- GlobeNewswire
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
BALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim 4th Annual Immunology & Neurology Day, which is taking place from November 14 – 15, 2022. Details on the fireside chat can be found below. Date:Tuesday, November 15,
